Navigation Links
GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA)

s regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

GlaxoSmithKline Forward-Looking Statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2005.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.

Stock Exchange Release no. 27/2007

CONTACT: Contact: Helle Husted, Sr. Director, Investor Relations, T:+45-33-44-77-30, E: hth@genmab.com

Ticker Symbol: (:GNMSF)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
2. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
3. Genmabs HuMax-EGFr Shows Broad Potential in Cancer Treatment
4. The Past, Present and Future of HLA Typing
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
11. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/31/2015)... , July 31, 2015  Boston Children,s Hospital ... from 3D printing of their anatomy before undergoing ... cerebrovascular malformations (abnormalities in the brain,s blood vessels) ... online today in the Journal of Neurosurgery: ... 3D printing and synthetic resins to create custom, ...
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... Calif., Feb. 10, 2011 PRO-DEX, INC. (Nasdaq: ... quarter and six months ended December 31, 2010. ... 8% to $6.2 million from $5.7 million for the corresponding ... the Company,s medical device products to its largest customer, and ...
... Cephalon, Inc. (Nasdaq: CEPH ) today reported ... compared to net sales of $2.152 billion for 2009.  Basic ... amortization expense and certain other items, adjusted net income for ... over the previous year.  This exceeded the company,s adjusted net ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 2Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 3Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 4Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 5Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 6Pro-Dex, Inc. Announces Fiscal Second Quarter and Six Month Results 7Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 2Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 3Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 4Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 5Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 6Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 7Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 8Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 9Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 10Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 11Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 12Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 13Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 14Cephalon Reported Record Sales, Adjusted Net Income and Cash From Operations in 2010 15
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ( http://evermaya.com/ ), ... handbag line will be named for Madeline Stuart, an 18-year-old model from Brisbane, ... recognized model with Down syndrome, gracing the front pages of publications across the ...
(Date:7/31/2015)... Minn. (PRWEB) , ... July 31, 2015 , ... ... is selected as a contributor for LeadingAge’s Center for Aging Services Technologies (CAST) ... designed to help long-term and post-acute care providers understand the benefits of using ...
(Date:7/31/2015)... York (PRWEB) , ... July 31, 2015 , ... Physical therapy for ... limits the patient's quality of life. It keeps the patient from doing what they want ... and may have a hard time using the stairs. The patient's exercise regime may be ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Radiology Business ... Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol Hill” ... founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of the ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent ... Court in the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini ... docket entry was made recording the minutes of the status conference, which was held ...
Breaking Medicine News(10 mins):Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4
... , , ... agenda of events, education sessions, new product introductions and a wide ... launched its annual Allscripts Client Experience (ACE) ... 2,700 attendees registered for the conference, driven by strong interest in ...
... /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS ... of the Company, will present at the Canaccord Adams 29th ... August 11, 2009 at 3:30 p.m. ET. , Interested parties ... the "Events" section of the homepage of the Company,s website ...
... ... ... $4,240 $5,215 ... 22%, Diluted EPS from Continuing Operations $0.51 $0.41, Special ...
... ... of Family Crisis. , ... (PRWEB) -- Once upon a time Denise found herself in the midst of a crisis. ... accident involving his son. She was very close to her brother and he needed her ...
... ... in PA, after the creative director lost his beloved mother to ARDS. Accent Media donated ... , ... 27, 2009 -- Acute Respiratory Distress Syndrome (ARDS) may not be one of the most ...
... autoimmune disease systemic lupus erythematosus (SLE) have an increased ... immune responses and treatment with immunosuppressive drugs. Because morbidity ... patients, it is recommended that patients with SLE get ... increase disease activity. Both antibody and cell-mediated responses are ...
Cached Medicine News:Health News:Allscripts User Conference Draws 2,700, Sets Attendance Record 2Health News:Allscripts User Conference Draws 2,700, Sets Attendance Record 3Health News:Allscripts User Conference Draws 2,700, Sets Attendance Record 4Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 2Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 3Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 4Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 5Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 6Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 7Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 8Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 9Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 10Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 11Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 12Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 13Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 14Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 15Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 16Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 17Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 18Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 19Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 20Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 21Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 22Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 23Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 24Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 25Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 26Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 27Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 28Health News:Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of $0.58 Per Share and GAAP Earnings of $0.51 Per Share 29Health News:Prepaid Emergency Travel Announces a Unique Service That Provides Peace of Mind During Family Emergencies 2Health News:ARDS Promotes Awareness with New Campaign 2Health News:Immune responses to flu vaccine are diminished in lupus patients 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: